Overview

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.
Phase:
Phase 2
Details
Lead Sponsor:
HemaQuest Pharmaceuticals Inc.
Collaborator:
Boston University
Treatments:
Arginine butyrate
Butyric Acid
Ganciclovir
Ganciclovir triphosphate
Valganciclovir